Phacilitate Leaders World


Fraser Wright

Fraser Wright

Co-Founder & Chief Technology Officer, Spark Therapeutics

Dr. Fraser Wright has been engaged for more than 20 years in the development of viral vector-based new biologic products in both industry and academic settings. Fraser previously served as the director of the Clinical Vector Core Laboratory at The Children's Hospital of Philadelphia, a world-class manufacturing facility that has designed, manufactured, characterized and certified recombinant adeno-associated viruses (AAV) and lentiviruses (rLenti) for human gene therapy trials. He also was a professor of pathology and laboratory medicine at the University of Pennsylvania. Fraser has led efforts in basic research, process and analytical methods development and GMP manufacturing and quality systems supporting translational research. He has overseen investigational product chemistry, manufacturing and controls for gene therapy vectors administered to more than 150 human subjects in 12 clinical studies. With basic training in biochemistry, immunology and virology, his primary research interests focus on the development and clinical translation of gene therapy vectors with the goal of achieving effective new treatments for serious human diseases. He previously served as director of development and clinical manufacturing at Avigen, Inc. He received his B.S. and Ph.D. in biochemistry from the University of Toronto.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman